SU2C and Genentech announced a Catalyst collaboration aimed at accelerating the development of new cancer treatments and combination therapies by providing funding and access to a dozen of the company’s medicines.
With major leadership changes, grant disruptions and terminations, and a stoked distrust in science, Steven Artandi, the director of Stanford Cancer Center, worries that young investigators will feel disenchanted by the U.S. research atmosphere and take their work and study elsewhere.
